Analysts See $-0.19 EPS for SenesTech, Inc. (SNES)

March 15, 2018 - By Stephen Andrade

 Analysts See $ 0.19 EPS for SenesTech, Inc. (SNES)

Analysts expect SenesTech, Inc. (NASDAQ:SNES) to report $-0.19 EPS on March, 29.After having $-0.28 EPS previously, SenesTech, Inc.’s analysts see -32.14 % EPS growth. The stock increased 4.28% or $0.03 during the last trading session, reaching $0.65. About 79,796 shares traded. SenesTech, Inc. (NASDAQ:SNES) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company has market cap of $10.26 million. The firm focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It currently has negative earnings. It is also developing a pipeline of fertility control and animal health products, including plant fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

More notable recent SenesTech, Inc. (NASDAQ:SNES) news were published by: which released: “Numerous Red Flags And Rats At SenesTech Inc (SNES)” on January 11, 2017, also with their article: “SenesTech, Inc. (SNES) Climbs 100% After Announcing Distribution Agreement …” published on October 23, 2017, published: “Meet Arizona’s newest public company” on December 09, 2016. More interesting news about SenesTech, Inc. (NASDAQ:SNES) were released by: and their article: “SenesTech, Inc. Announces Closing of Initial Public Offering” published on December 13, 2016 as well as‘s news article titled: “SenesTech Launches ContraPest┬« Fertility Control Product “Research Sales”” with publication date: December 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: